AstraZeneca inks $310M deal for asthma programs

AstraZeneca is stepping up its deal-making efforts with a pact to acquire Verus Pharmaceuticals' pediatric asthma programs for a potential $310 million. Verus gets $30 million of that up front with $280 million in scheduled milestones. The deal includes the North American rights to Captisol enabled budesonide solution, a short-acting beta agonist solution, a customized version of eFlow for use with both medications, and other IP. 

"This transaction allows us to refocus our time and resources on our other emerging development programs, including those targeting unmet needs associated with related atopic diseases and conditions," said Verus president Robert W. Keith. Verus was a 2005 Fierce 15 company.

- check out the release for more info

PLUS: AstraZeneca wants some fresh eyes on its financial challenges. The drug maker is casting outside of pharma for a new CFO to replace Jon Symonds, who quit abruptly in June to join Goldman Sachs. Report

Related Articles:
Start-up opens with $98M in financing. Report
AstraZeneca cuts 7,600 jobs. Report
AstraZeneca announces restructuring and buyout. Report
AstraZeneca to continue ambitious deal-making. Report
AstraZeneca lays out road map for recovery. Report

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.